Remote Monitoring of CGM Data in Pediatric Patients With Newly Diagnosed Type 1 Diabetes (T1D)
Launched by STANFORD UNIVERSITY · May 28, 2019
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Based on alerts from GluVue, care team members will proactively reach out to patients and their families for more frequent dose adjustments. We will assess if remote monitoring facilitates contact between the care team and patients and improves glycemic control.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All individuals within one month of T1D diagnosis seen at the Stanford Children's Diabetes Clinic
- • Individuals who plan to receive follow up care at the Stanford Children's Diabetes Clinic
- • Individuals who agree to CGM data integration into the electronic medical record (EMR) for remote monitoring
- • Age: birth to \< 21 years of age
- Exclusion Criteria:
- • Diabetes diagnosis other than T1D
- • Diagnosis of diabetes \> 1 month prior to initial visit
- • Individuals with the intention of obtaining diabetes care at another clinic
- • Individuals who do not consent to CGM use, CGM data integration, or remote monitoring
- • Individuals \> 21 years of age
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Palo Alto, California, United States
Patients applied
Trial Officials
Priya Prahalad, MD, PhD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials